Advertisement

 

 

A cross-reacting material CRM197 conjugate vaccine induces diphtheria toxin neutralizing antibody response in children and adolescents infected or not with HIV.

A cross-reacting material CRM197 conjugate vaccine induces diphtheria toxin neutralizing antibody response in children and adolescents infected or not with HIV.
Author Information (click to view)

Silva GP, Santos RS, Pereira-Manfro WF, Ferreira B, Barreto DM, Frota ACC, Hofer CB, Milagres LG,


Silva GP, Santos RS, Pereira-Manfro WF, Ferreira B, Barreto DM, Frota ACC, Hofer CB, Milagres LG, (click to view)

Silva GP, Santos RS, Pereira-Manfro WF, Ferreira B, Barreto DM, Frota ACC, Hofer CB, Milagres LG,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Vaccine 2017 06 0735(31) 3803-3807 pii 10.1016/j.vaccine.2017.05.080

Abstract

Anti-diphtheria antibody levels decrease with aging, and frequent booster vaccinations are required to maintain herd immunity. We analyzed the diphtheria toxin neutralizing antibody (DT-Nab) response induced by a conjugate vaccine (meningococcal C polysaccharide-CRM197) in HIV-vertically infected (HI) children and adolescents and healthy controls (HC) with matched age. We report the association of DT-Nab with the bactericidal antibodies to serogroup C meningococcus (MenC). Before vaccination, 21 HI patients (50%) had no protection against diphtheria (≤0.01IU/ml of antibody) and only 8 (19%) showed complete protection (≥0.1IU/ml). About half of the HC (56%) had complete protection before immunization and 6 subjects (12%) had no protection against diphtheria. After one and two vaccine injections, 96% of HC and 64% of HI vaccinees, respectively, showed full protection against diphtheria. These data indicate that CRM197 was able to induce primary and/or booster response in both groups of individuals.

Submit a Comment

Your email address will not be published. Required fields are marked *

eight − 6 =

[ HIDE/SHOW ]